Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Chimeric monoclonal antiplatelet antibody/glycoprotein IIb/IIIa-receptor inhibitor.
- RESTRICTED FOR USE IN CRITICAL CARE AREAS; CARDIOLOGY SHOULD BE CONSULTED.
- Experience in children limited. One study of 15 pediatric patients (Pediatrics Vol. 109 No. 1 Jan 2002 Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki Disease) used the same dosing guidelines as in adults for a 12 hour infusion
Reconstitution and Stability:
- Available as a 2 mg/mL injection
- Vial is stable 7 days refrigerated once punctured
- Diluted solutions (36 mcg/mL) stable 30 hours at room temperature
- DO NOT SHAKE
- Filter through a low protein-binding filter (0.2 or 0.22 micrometer)
- Solutions Compatible: D5W, NS
- NO OTHER drugs should be administered with abciximab
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
Infusion time: over at least 1 minute
|IV Intermittent Infusion
|IV Continuous Infusion
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Adults: 0.25 mg/kg loading dose
0.125 mcg/kg/min (maximum 10 mcg/min)
Potential hazards of parenteral administration:
- Thrombocytopenia, bleeding, hematoma (monitor potential bleeding sites)
- Hypotension, bradycardia
- Nausea, vomiting
- Safety and efficacy of abciximab have been investigated with concomitant administration of aspirin and heparin
- Monitoring: clotting time, PT, aPTT, hemoglobin, hematocrit, platelet count
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.